CV-11974, angiotensin II type I receptor antagonist, protects against ischemia-reperfusion injury of the small intestine in rats. 2006

Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
Biomedical Safety Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.

BACKGROUND Angiotensin II has been implicated in the pathogenesis of vascular inflammation in various organs. The aim of the present study was to examine the effect of angiotensin II type I receptor antagonist, CV-11974, on reperfusion-induced small intestinal injury in rats. METHODS Intestinal damage was induced by clamping both the superior mesenteric artery and the celiac trunk for 30 min followed by reperfusion for 60 min in male Wistar rats. CV-11974 was given to the rats by intravenous injection 1 h before the vascular clamping. The intestinal mucosal injury and inflammation were evaluated by biochemical markers and histological findings. Thiobarbituric acid reactive substances and tissue-associated myeloperoxidase (MPO) activity were measured in the gastric mucosa as indices of lipid peroxidation and neutrophil infiltration. The expressions of pro-inflammatory cytokines (CINC-1) in intestinal mucosa were measured by enzyme-linked immunosorbent assay (ELISA) and reverse transcription-PCR (RT-PCR). In additional experiments with an in vitro flow system, human neutrophils were perfused on human umbilical vein endothelial cells (HUVEC) pretreated with anoxia-reoxygenation with or without CV-11974 and then the adhesive neutrophils were counted. RESULTS Reperfusion after ischemia resulted in an increase in luminal protein concentrations, hemoglobin concentrations, thiobarbituric acid reactive substances, and MPO activity. Pretreatment with CV-11974 significantly inhibited the increases in these parameters. CV-11974 also inhibited increases in intestinal CINC-1 protein and mRNA expression induced by ischemia-reperfusion. Moreover, in an in vitro study, CV-11974 significantly inhibited the adherence of neutrophils to HUVEC exposed to reoxygenation after anoxia. CONCLUSIONS These results suggest that the blockade of angiotensin II type I receptor by treatment with CV-11974 remarkably reduced the reperfusion-induced intestinal injury.

UI MeSH Term Description Entries
D007410 Intestinal Diseases Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM. Disease, Intestinal,Diseases, Intestinal,Intestinal Disease
D007413 Intestinal Mucosa Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI. Intestinal Epithelium,Intestinal Glands,Epithelium, Intestinal,Gland, Intestinal,Glands, Intestinal,Intestinal Gland,Mucosa, Intestinal
D007421 Intestine, Small The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM. Small Intestine,Intestines, Small,Small Intestines
D008297 Male Males
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
April 2001, Transplantation,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
July 1995, Journal of hypertension,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
April 1994, Clinical and experimental pharmacology & physiology,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
January 1994, Blood pressure. Supplement,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
January 2007, Molecular medicine (Cambridge, Mass.),
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
March 1999, The Journal of surgical research,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
October 2013, International journal of cardiology,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
February 2002, Transplantation,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
January 2016, Microbiology and immunology,
Tomohisa Takagi, and Norimasa Yoshida, and Yutaka Isozaki, and Makoto Shimozawa, and Kazuhiro Katada, and Hiroki Manabe, and Osamu Hanada, and Satoshi Kokura, and Hiroshi Ichikawa, and Yuji Naito, and Takeshi Okanoue, and Toshikazu Yoshikawa
January 2003, Kidney international,
Copied contents to your clipboard!